Merck KGaA
Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea. Headquartered in Daejeon, South Korea.
About this organization
Overview
The source site (biotechreality.com) is a biopharma news and information publication. The excerpts contain headlines and summaries about Merck KGaA, not the company's own service descriptions.
Reported activity
- CDMO divestment: A headline dated 3 November 2026 reports that Lonza is set to acquire Merck KGaA's life science CDMO business for mid-triple-digit million euros.
- Daejeon bioprocessing center: A headline dated 30 October 2026 reports the opening of a Merck bioprocessing center in Daejeon, South Korea, with a €300 million investment to expand Asia-Pacific biologics supply.
The excerpts do not establish Merck KGaA's current core business model, service lines, certifications, or headcount.
Locations
Daejeon Bioprocessing Center
Daejeon · South Korea
Submit a verified review for this organization.
Markdown mirror: /companies/merck-kgaa.md